1. GPCR/G Protein
  2. Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid receptors are currently classified into three groups: central (CB1), peripheral (CB2) and GPR55, all of which are G-protein-coupled. CB1 receptors are primarily located at central and peripheral nerve terminals. CB2 receptors are predominantly expressed in non-neuronal tissues, particularly immune cells, where they modulate cytokine release and cell migration. Recent reports have suggested that CB2 receptors may also be expressed in the CNS. GPR55 receptors are non-CB1/CB2 receptors that exhibit affinity for endogenous, plant and synthetic cannabinoids. Endogenous ligands for cannabinoid receptors have been discovered, including anandamide and 2-arachidonylglycerol.

Cannabinoid Receptor Related Products (19):

Cat. No. Product Name Effect Purity
  • HY-13291
    WIN 55,212-2 Mesylate Agonist 98.98%
    WIN 55,212-2 (Mesylate) is a potent aminoalkylindole cannabinoid (CB) receptor agonist with Kis of 62.3 and 3.3 nM for human recombinant CB1 and CB2 receptors, respectively.
  • HY-15421
    AM630 Antagonist 99.32%
    AM630 is a selective CB2 antagonist with Ki of 31.2 nM, and displays 165-fold selectivity over CB1 receptors.
  • HY-15443
    AM251 Antagonist 99.93%
    AM251 is a selective cannabinoid (CB)1 receptor antagonist with IC50 of 8 nM, also acts as an agonist at micromolar concentration.
  • HY-10013
    Taranabant Agonist 99.46%
    Taranabant is a highly potent and selective cannabinoid 1 (CB1) receptor inverse agonist that inhibits the binding and functional activity of various agonists, with a binding Ki of 0.13 nM for the human CB1R in vitro.
  • HY-14137
    Rimonabant Hydrochloride Antagonist 98.34%
    Rimonabant hydrochloride is a cannabinoid receptor antagonist, which binds selectively to central cannabinoid receptors (CB1) with high affinity (Ki=2 nM).
  • HY-B0151
    Pregnenolone Inhibitor >98.0%
    Pregnenolone is an endogenous steroid hormone for inhibition of M1 receptor and M3 receptor-mediated currents with IC50 of 11.4 μM and 6.0 μM, respectively.
  • HY-18697
    JD-5037 Antagonist >98.0%
    JD-5037 is a novel, peripherally restricted CB1R antagonist with an IC50 of 1.5 nM.
  • HY-14791A
    (±)-SLV319 Antagonist
    (±)-SLV319 is the racemate of SLV319.
  • HY-13288
    Org 27569 Modulator 99.59%
    Org 27569 is a potent CB1 receptor allosteric modulator, which increases agonist binding, yet blocks agonist-induced CB1 signaling.
  • HY-10871
    Otenabant Antagonist
    Otenabant is a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.
  • HY-12761
    A-836339 Agonist 99.56%
    A-836339 is a cannabinoid CB2 receptor-selective agonist; exhibits high potencies at CB(2) and selectivity over CB(1) receptors.
  • HY-12790
    CB1-IN-1 Antagonist
    CB1-IN-1 is a peripherally restricted CB1R antagonist, with Ki of 0.3 nM and 21 nM for CB1R (EC50 = 3 nM) and CB2R, respectively.
  • HY-15854
    JWH-133 Agonist
    JWH 133 is a potent CB2 selective agonist with Ki of 3.4 nM, 200-fold selective over CB1 receptors.
  • HY-100488
    Bay 59-3074 Agonist 98.01%
    Bay 59-3074 is a novel, selective CB1/CB2 receptor partial agonist with Ki values of 48.3 and 45.5 nM at human CB1 and CB2 receptors respectively . Orally active CB1 agonist in vivo.
  • HY-10871A
    Otenabant Hydrochloride Antagonist
    Otenabant Hydrochloride is a potent and selective cannabinoid receptor CB1 antagonist with Ki of 0.7 nM, exhibits 10,000-fold greater selectivity against human CB2 receptor.
  • HY-15420
    BML-190 Agonist
    BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively).
  • HY-10013B
    Taranabant ((1R,2R)stereoisomer)
    Taranabant (1R,2R)stereoisomer is the R-enantiomer of Taranabant.
  • HY-15451
    MDA 19 Agonist
    MDA 19 is a selective human CB2 receptor agonist with Ki of 43.3 nM.
  • HY-14136
    Rimonabant Inhibitor
    Rimonabant(SR141716) is a selective central cannabinoid (CB1) receptor inverse agonist with Ki of 1.8 nM.